Department of Bacteriology, Mycology and Parasitology, Statens Serum Institut, Artillerivej, Copenhagen, Denmark.
J Clin Gastroenterol. 2010 Feb;44(2):85-90. doi: 10.1097/MCG.0b013e3181bb86ba.
Metronidazole constitutes a mainstay in the antimicrobial therapy of intestinal protozoa, and is also traditionally considered first-line therapy in cases where there is a requirement to treat Blastocystis, a common protist of disputable clinical significance. Many compounds have been used in attempts to eradicate the parasite, and an accumulating body of data indicates that successful antimicrobial eradication of Blastocystis is far from straightforward. This review focuses on some issues that prevent us from reaching a clear understanding of how to eradicate Blastocystis based on chemotherapeutic intervention, by focusing on conflicting reports on the efficacy of metronidazole and other compounds and study design and data limitations. The review provides a comprehensive overview of antimicrobials used to target Blastocystis, and discusses issues pertaining to drug resistance, treatment failure, and reinfection. Finally, key methodological and molecular diagnostic tools that will assist in the generation of data required to improve current knowledge are identified and discussed.
甲硝唑是治疗肠道原虫病的主要药物，在需要治疗 Blastocystis 时，也被传统认为是一线治疗药物，Blastocystis 是一种具有争议性临床意义的常见原生动物。为了消灭这种寄生虫，人们尝试了许多化合物，越来越多的数据表明，成功地用抗菌药物消灭 Blastocystis 并非易事。这篇综述重点讨论了一些问题，这些问题使得我们难以根据化学治疗干预来明确了解如何消灭 Blastocystis，具体内容包括甲硝唑和其他化合物疗效的相互矛盾的报告，以及研究设计和数据限制。该综述全面概述了用于靶向 Blastocystis 的抗菌药物，并讨论了耐药性、治疗失败和再感染等问题。最后，确定并讨论了有助于生成改善现有知识所需数据的关键方法学和分子诊断工具。
